Jeffrey M. Witkin

Affiliations: 
Eli Lilly, Indianapolis, IN, United States 
Google:
"Jeffrey Witkin"
Mean distance: 17.34 (cluster 19)
 
SNBCP
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Witkin JM, Cerne R, Newman AH, et al. (2021) N-Substituted-3-alkoxy-derivatives of dextromethorphan are functional NMDA receptor antagonists in vivo:Evidence from an NMDA-induced seizure model in rats. Pharmacology, Biochemistry, and Behavior. 173154
Pandey KP, Khan ZA, Golani LK, et al. (2020) Design, synthesis and characterization of novel gamma‑aminobutyric acid type A receptor ligands. Arkivoc : Free Online Journal of Organic Chemistry. 2020: 242-256
Knutson DE, Smith JL, Ping X, et al. (2020) The Imidazodiazepine Anticonvulsant, KRM-II-81, Produces Novel, Non-diazepam-like Antiseizure Effects. Acs Chemical Neuroscience
Biggerstaff A, Kivell B, Smith JL, et al. (2020) The α2,3-selective potentiators of GABA receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects, and block chemotherapy-induced hyperalgesia, in mice without tolerance development. Pharmacology, Biochemistry, and Behavior. 172996
Witkin JM, Li G, Golani LK, et al. (2019) The positive allosteric modulator of α2/3-containing GABAA receptors, KRM-II-81, is active in pharmaco-resistant models of epilepsy and reduces hyperexcitability after traumatic brain injury. The Journal of Pharmacology and Experimental Therapeutics
Witkin JM, Ping X, Cerne R, et al. (2019) The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs:The example of CERC-611 and KRM-II-81. Brain Research. 146356
Eiler WJA, Gleason SD, Smith JL, et al. (2019) A medium throughput rodent model of relapse from addiction with behavioral and pharmacological specificity. Pharmacology, Biochemistry, and Behavior
Balcer OM, Seager MA, Gleason SD, et al. (2018) Evaluation of 5-HT receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice. Behavioural Brain Research. 360: 270-278
Maxwell J, Gleason SD, Falcone J, et al. (2018) Effects of 5-HT Receptor Antagonists on Behaviors of Mice that Detect Drugs Used in the Treatment of Anxiety, Depression, or Schizophrenia. Behavioural Brain Research
Witkin JM, Shenvi RA, Li X, et al. (2018) Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies. Biochemical Pharmacology
See more...